MCID: BLD051
MIFTS: 48

Blood Coagulation Disease

Categories: Blood diseases, Genetic diseases

Aliases & Classifications for Blood Coagulation Disease

MalaCards integrated aliases for Blood Coagulation Disease:

Name: Blood Coagulation Disease 12 15 17
Blood Coagulation Disorders 75 44 72
Postpartum Coagulation Defect with Delivery 12
Postpartum Coagulation Defect 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1247
ICD9CM 35 286
MeSH 44 D001778
NCIt 50 C2902
SNOMED-CT 68 64779008
ICD10 33 D68.9 O72.3
UMLS 72 C0005779

Summaries for Blood Coagulation Disease

MalaCards based summary : Blood Coagulation Disease, also known as blood coagulation disorders, is related to inherited blood coagulation disease and antithrombin iii deficiency. An important gene associated with Blood Coagulation Disease is VWF (Von Willebrand Factor), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Phylloquinone and Anti-inhibitor coagulant complex have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and brain, and related phenotypes are no effect and hematopoietic system

Wikipedia : 75 Coagulopathy (also called a bleeding disorder) is a condition in which the blood's ability to coagulate... more...

Related Diseases for Blood Coagulation Disease

Diseases in the Blood Coagulation Disease family:

Inherited Blood Coagulation Disease

Diseases related to Blood Coagulation Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 237, show less)
# Related Disease Score Top Affiliating Genes
1 inherited blood coagulation disease 32.8 VWF SERPINC1 ITGB3 ITGA2B GP9 GP1BA
2 antithrombin iii deficiency 32.6 SERPINC1 MTHFR F2
3 bleeding disorder, platelet-type, 16 32.5 ITGB3 ITGA2B
4 pseudo-von willebrand disease 32.5 VWF GP9 GP1BA
5 acquired von willebrand syndrome 32.5 VWF GP1BA F9 F8
6 prothrombin deficiency, congenital 32.5 SERPINC1 F2
7 gray platelet syndrome 32.4 VWF GP9 CD40LG
8 factor vii deficiency 32.3 F9 F8 F7 F3 F2
9 hemophilia b 32.1 SERPINC1 F9 F8 F7 F3 F2
10 factor v deficiency 32.1 VWF F9 F8 F7 F3 F2
11 bernard-soulier syndrome 31.4 VWF THPO ITGB3 ITGA2B GP9 GP1BA
12 glanzmann thrombasthenia 31.2 VWF ITGB3 ITGA2B GP9 GP1BA F9
13 factor viii deficiency 31.2 VWF F8 F2
14 heparin-induced thrombocytopenia 30.9 SERPINC1 F3 CD40LG
15 liver cirrhosis 30.8 THPO SERPINC1 F3 F2
16 dysfibrinogenemia 30.8 THBD SERPINC1 F2
17 hemophilia a 30.7 VWF F9 F8 F7 F3
18 hemophilia 30.7 VWF F9 F8 F7 F3 F2
19 vasculitis 30.6 VWF THBD CD40LG
20 portal hypertension 30.6 VWF THPO F2
21 placental abruption 30.6 THBD SERPINC1 MTHFR F2
22 thrombotic thrombocytopenic purpura 30.5 VWF THBD F3 ADAMTS13
23 varicose veins 30.4 VWF SERPINC1 MTHFR F2
24 thrombophlebitis 30.4 SERPINC1 MTHFR F8 F2
25 disseminated intravascular coagulation 30.4 THBD SERPINC1 F9 F7 F3 F2
26 von willebrand's disease 30.4 VWF GP1BA F9 F8 F3 F2
27 factor x deficiency 30.1 VWF SERPINC1 F9 F7 F3 F2
28 polycythemia vera 29.9 THPO THBD PF4 MPL ITGB3
29 hellp syndrome 29.7 VWF THBD SERPINC1 MTHFR F3 F2
30 thrombophilia 29.7 VWF THBD SERPINC1 MTHFR F9 F8
31 thrombophilia due to thrombin defect 29.7 VWF THBD SERPINC1 MTHFR F8 F3
32 thrombocytopenia 29.4 THPO PF4 MPL ITGB3 ITGA2B GP9
33 vascular disease 29.3 VWF THBD SERPINC1 MTHFR ITGB3 GP1BA
34 thrombophilia due to activated protein c resistance 29.1 VWF THBD SERPINC1 PF4 MTHFR F9
35 purpura 29.1 VWF THPO THBD SERPINC1 MPL ITGB3
36 thrombosis 28.7 VWF THBD SERPINC1 PF4 MTHFR GP1BA
37 bleeding disorder, platelet-type, 17 11.1
38 scott syndrome 11.1
39 quebec platelet disorder 11.1
40 bleeding disorder, platelet-type, 12 11.1
41 platelet glycoprotein iv deficiency 11.1
42 bleeding disorder, platelet-type, 8 11.1
43 bleeding disorder, platelet-type, 14 11.1
44 bleeding disorder, platelet-type, 9 11.1
45 bleeding disorder, platelet-type, 11 11.1
46 bleeding disorder, platelet-type, 15 11.1
47 bleeding disorder, platelet-type, 18 11.1
48 bleeding disorder, platelet-type, 19 11.1
49 bleeding disorder, platelet-type, 20 11.1
50 factor xiii deficiency 11.1
51 factor v and factor viii, combined deficiency of, 1 11.1
52 factor v and factor viii, combined deficiency of, 2 11.1
53 fainting 10.8 VWF F8
54 unilateral absence of a pulmonary artery 10.8 VWF THBD
55 cerebral falx meningioma 10.8 F3 F2
56 intestinal impaction 10.8 SERPINC1 F3 F2
57 qualitative platelet defect 10.8 VWF F3 F2
58 giant hemangioma 10.8 SERPINC1 F3 F2
59 sagittal sinus thrombosis 10.7 SERPINC1 F3 F2
60 cerebral arteritis 10.7 VWF F8
61 blue toe syndrome 10.7 SERPINC1 F3 F2
62 purpura fulminans 10.7 SERPINC1 F3 F2
63 bombay phenotype 10.7 VWF ADAMTS13
64 brachydactyly, type d 10.7 VWF F8 F2
65 peripheral vertigo 10.7 SERPINC1 F3 F2
66 cerebral sinovenous thrombosis 10.7 F3 F2
67 acquired hemophilia 10.7 F9 F8 F3
68 acquired hemophilia a 10.7 F9 F8 F3
69 prothrombin deficiency 10.7 F7 F3 F2
70 hypersplenism 10.7 THPO SERPINC1 F2
71 alcohol-related birth defect 10.7 F8 F3 F2
72 splenic disease 10.7 THPO F3 F2
73 post-thrombotic syndrome 10.7 SERPINC1 F8 F2
74 intermittent claudication 10.7 VWF SERPINC1 F2
75 cardiac tamponade 10.7 F9 F8 F2
76 factor xii deficiency 10.7 SERPINC1 F9 F3
77 anterior cranial fossa meningioma 10.7 F7 F3 F2
78 thrombocytopenia 3 10.7 THPO MPL
79 aspirin allergy 10.7 SERPINC1 ITGA2B
80 thrombocythemia 1 10.7 THPO MPL
81 spinal cord infarction 10.7 SERPINC1 MTHFR F2
82 active peptic ulcer disease 10.7 VWF F2
83 korean hemorrhagic fever 10.7 VWF SERPINC1 F3 F2
84 lateral sinus thrombosis 10.7 MTHFR F9
85 sticky platelet syndrome 10.7 SERPINC1 ITGB3
86 spotted fever 10.7 VWF THBD F2
87 intracranial embolism 10.6 SERPINC1 F2
88 platelet aggregation, spontaneous 10.6 VWF SERPINC1 PF4
89 afibrinogenemia, congenital 10.6 VWF SERPINC1 F3 F2
90 von willebrand disease, type 1 10.6 VWF F8 F3 F2
91 retinal vascular occlusion 10.6 SERPINC1 MTHFR F2
92 malignant skin fibrous histiocytoma 10.6 ITGA2B F9 F7
93 intermediate coronary syndrome 10.6 VWF SERPINC1 ITGA2B F3
94 alpha-2-plasmin inhibitor deficiency 10.6 SERPINC1 F2
95 central retinal vein occlusion 10.6 SERPINC1 MTHFR F2
96 malignant dermis tumor 10.6 ITGA2B F9 F7
97 mesenteric vascular occlusion 10.6 MTHFR F7 F2
98 retinal vein occlusion 10.6 SERPINC1 MTHFR F2
99 afibrinogenemia 10.6 VWF F8 F3 F2
100 fetal and neonatal alloimmune thrombocytopenia 10.6 ITGB3 ITGA2B GP1BA
101 sudden sensorineural hearing loss 10.6 MTHFR ITGB3 F2
102 dyskeratosis congenita, autosomal dominant 6 10.6 THPO MPL
103 hemolytic uremic syndrome, atypical 1 10.6 VWF THBD ADAMTS13
104 hemarthrosis 10.6 VWF F9 F8 F7
105 arteries, anomalies of 10.6 VWF SERPINC1 ITGA2B F3
106 autosomal dominant macrothrombocytopenia 10.6 ITGB3 ITGA2B GP1BA
107 osteonecrosis 10.6 SERPINC1 MTHFR F2
108 homocysteinemia 10.6 SERPINC1 MTHFR F2
109 placenta disease 10.6 SERPINC1 MTHFR F3
110 infective endocarditis 10.6 ITGB3 GP1BA F2
111 hepatic veno-occlusive disease 10.6 THPO THBD SERPINC1 F3
112 legg-calve-perthes disease 10.5 THBD SERPINC1 CD40LG
113 exanthema subitum 10.5 THPO ITGA2B CD40LG
114 hemolytic-uremic syndrome 10.5 VWF THBD F3 ADAMTS13
115 thrombocytopenia-absent radius syndrome 10.5 THPO MPL GP1BA
116 hepatic infarction 10.5 SERPINC1 MTHFR F3 F2
117 blood protein disease 10.5 SERPINC1 MTHFR F3 F2
118 leech infestation 10.5 SERPINC1 PF4 F3 F2
119 branch retinal artery occlusion 10.5 SERPINC1 MTHFR F3 F2
120 pulmonary artery disease 10.5 SERPINC1 MTHFR F3 F2
121 protein s deficiency 10.5 SERPINC1 MTHFR F3 F2
122 intracranial hypertension 10.5 SERPINC1 MTHFR F3 F2
123 livedoid vasculitis 10.5 SERPINC1 MTHFR F8 F2
124 acute myocardial infarction 10.5 VWF SERPINC1 ITGA2B F3
125 patent foramen ovale 10.5 SERPINC1 MTHFR F2
126 retinal artery occlusion 10.5 SERPINC1 MTHFR F8 F2
127 portal vein thrombosis 10.5 SERPINC1 MTHFR F7 F2
128 grange syndrome 10.5 VWF THBD MTHFR F3
129 eclampsia 10.5 THBD SERPINC1 MTHFR F2
130 peripheral vascular disease 10.5 VWF THBD SERPINC1 F3 F2
131 nonarteritic anterior ischemic optic neuropathy 10.5 SERPINC1 MTHFR GP1BA F2
132 thrombocytosis 10.4 THPO SERPINC1 MPL F3 F2
133 factor xi deficiency 10.4 THBD SERPINC1 F9 F3 F2
134 megakaryocytic leukemia 10.4 VWF THPO PF4 ITGA2B
135 catastrophic antiphospholipid syndrome 10.4 MTHFR F3 CD40LG ADAMTS13
136 femoral neuropathy 10.4 F3 F2
137 hepatic vascular disease 10.4 VWF SERPINC1 MTHFR F3 F2
138 fournier gangrene 10.4 SERPINC1 F8 F3 F2 CD40LG
139 coronary thrombosis 10.4 VWF SERPINC1 ITGB3 GP1BA F3
140 arteritic anterior ischemic optic neuropathy 10.4 MTHFR ITGB3 GP1BA F2
141 cold urticaria 10.4 SERPINC1 PF4
142 vein disease 10.4 SERPINC1 MTHFR F8 F3 F2
143 budd-chiari syndrome 10.4 SERPINC1 MTHFR F7 F3 F2
144 marantic endocarditis 10.4 THBD SERPINC1 MTHFR F3 F2
145 protein c deficiency 10.3 THBD SERPINC1 MTHFR F9 F2
146 cerebrovascular disease 10.3 VWF MTHFR ITGA2B F7 F2
147 thrombocytopenic purpura, autoimmune 10.3 THPO MPL ITGB3 ITGA2B GP1BA
148 thrombocytopenia due to platelet alloimmunization 10.3 THPO MPL ITGB3 ITGA2B GP9
149 von willebrand disease, type 3 10.3 VWF GP1BA F8 F3 ATAT1
150 coronary artery anomaly 10.3 PF4 F7 F2
151 pulmonary embolism 10.3 VWF SERPINC1 MTHFR F9 F3 F2
152 ischemic neuropathy 10.2 MTHFR F2
153 intracranial thrombosis 10.2 VWF SERPINC1 MTHFR ITGA2B F8 F3
154 pre-eclampsia 10.2 VWF THBD SERPINC1 MTHFR F3 F2
155 liver disease 10.1
156 bone marrow cancer 10.1 VWF THPO THBD PF4 MPL ITGB3
157 cryptogenic cirrhosis 10.1 MTHFR F2
158 arteriosclerosis 10.1
159 autoimmune disease of blood 10.0 VWF THPO MPL ITGB3 ITGA2B GP1BA
160 systemic lupus erythematosus 10.0 VWF THBD F3 F2 CD40LG ADAMTS13
161 leukemia 10.0
162 acute leukemia 10.0
163 pancreatitis 10.0
164 adenoma 10.0
165 malaria 9.9 VWF THBD SERPINC1 PF4 F3 CD40LG
166 atherosclerosis susceptibility 9.9
167 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.9
168 hypogonadotropic hypogonadism 9.9
169 pyelonephritis 9.9
170 duodenal ulcer 9.9
171 hemangioma 9.9
172 acute pancreatitis 9.9
173 glomerulonephritis 9.9
174 shwartzman phenomenon 9.9
175 hyperthyroidism 9.9
176 collagen disease 9.9
177 splenomegaly 9.9
178 brain injury 9.9
179 thrombasthenia 9.9 MTHFR ITGB3 ITGA2B GP9 GP1BA F3
180 antiphospholipid syndrome 9.8 VWF THBD SERPINC1 MTHFR F3 F2
181 primary thrombocytopenia 9.8 VWF THPO MPL ITGB3 ITGA2B GP1BA
182 heart disease 9.8 VWF SERPINC1 PF4 MTHFR F8 F7
183 alcohol dependence 9.8
184 hemangioma-thrombocytopenia syndrome 9.8
185 hyperheparinemia 9.8
186 prader-willi syndrome 9.8
187 myeloma, multiple 9.8
188 ocular motor apraxia 9.8
189 leukemia, acute myeloid 9.8
190 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 9.8
191 heparin cofactor ii deficiency 9.8
192 deficiency anemia 9.8
193 metabolic acidosis 9.8
194 intrahepatic cholestasis of pregnancy 9.8
195 chronic eosinophilic leukemia 9.8
196 asphyxia neonatorum 9.8
197 respiratory failure 9.8
198 neutropenia 9.8
199 cholestasis 9.8
200 obstructive jaundice 9.8
201 hepatitis c 9.8
202 hyperuricemia 9.8
203 gaucher's disease 9.8
204 cholecystitis 9.8
205 leptospirosis 9.8
206 gastroenteritis 9.8
207 glycogen storage disease 9.8
208 hyperthyroxinemia 9.8
209 prostatic adenoma 9.8
210 pulmonary tuberculosis 9.8
211 mastocytosis 9.8
212 insulinoma 9.8
213 arteriosclerosis obliterans 9.8
214 kidney disease 9.8
215 polycythemia 9.8
216 lung disease 9.8
217 myeloid leukemia 9.8
218 lupus erythematosus 9.8
219 macroglobulinemia 9.8
220 homocystinuria 9.8
221 diabetes mellitus 9.8
222 meningitis 9.8
223 47,xyy 9.8
224 meningococcemia 9.8
225 cytomegalovirus infection 9.8
226 hypoxia 9.8
227 rapidly involuting congenital hemangioma 9.8
228 drug-induced vasculitis 9.8
229 acute radiation syndrome 9.8
230 acute liver failure 9.8
231 rare surgical neurologic disease 9.8
232 stroke, ischemic 9.6 VWF THBD SERPINC1 PF4 MTHFR F7
233 von willebrand disease, type 2 9.6 VWF ITGB3 ITGA2B GP1BA F8 F7
234 essential thrombocythemia 9.4 VWF THPO THBD PF4 MPL ITGB3
235 blood platelet disease 8.9 VWF THPO SERPINC1 PF4 MPL ITGB3
236 hemorrhagic disease 8.8 VWF THPO THBD SERPINC1 PF4 MPL
237 myocardial infarction 8.6 VWF THBD SERPINC1 PF4 MTHFR ITGB3

Graphical network of the top 20 diseases related to Blood Coagulation Disease:



Diseases related to Blood Coagulation Disease

Symptoms & Phenotypes for Blood Coagulation Disease

GenomeRNAi Phenotypes related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

26 (showing 1, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ADAMTS13 ATAT1 CD40LG F2 F3 F7

MGI Mouse Phenotypes related to Blood Coagulation Disease:

46 (showing 7, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 ADAMTS13 ATAT1 CD40LG F2 F3 F8
2 homeostasis/metabolism MP:0005376 10.19 ADAMTS13 CD40LG F2 F3 F7 F8
3 cardiovascular system MP:0005385 10.1 CD40LG F2 F3 F7 F9 ITGA2B
4 embryo MP:0005380 9.97 F2 F3 F9 ITGA2B ITGB3 MPL
5 immune system MP:0005387 9.97 ADAMTS13 CD40LG F2 F3 F8 F9
6 mortality/aging MP:0010768 9.8 ADAMTS13 ATAT1 CD40LG F2 F3 F7
7 reproductive system MP:0005389 9.28 ATAT1 CD40LG F2 F8 ITGA2B ITGB3

Drugs & Therapeutics for Blood Coagulation Disease

Drugs for Blood Coagulation Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 214, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phylloquinone Approved, Investigational Phase 4 84-80-0
2
Anti-inhibitor coagulant complex Approved, Investigational Phase 4
3
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
4
Tranexamic Acid Approved Phase 4 1197-18-8 5526
5 fluindione Approved, Investigational Phase 4 957-56-2
6
Phenindione Approved, Investigational Phase 4 83-12-5 4760
7
Protein C Approved Phase 4
8
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
9
Enoxaparin Approved Phase 4 9005-49-6 772
10
Dalteparin Approved Phase 4 9005-49-6
11
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
12
Edoxaban Approved Phase 4 480449-70-5
13
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
14
Thrombin Approved, Investigational Phase 4
15
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
16
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
17
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
18 Menaquinone Investigational Phase 4 1182-68-9
19 Hydroxyethyl Starch Derivatives Phase 4
20 Plasma Substitutes Phase 4
21 Blood Substitutes Phase 4
22 Micronutrients Phase 4
23 Trace Elements Phase 4
24 Coagulants Phase 4
25 Vitamins Phase 4
26 Antifibrinolytic Agents Phase 4
27 naphthoquinone Phase 4
28 Vitamin K Phase 4
29 Hemostatics Phase 4
30 Nutrients Phase 4
31 Fibrinolytic Agents Phase 4
32 Hirudins Phase 4
33 polysaccharide-K Phase 4
34 Calcium, Dietary Phase 4
35 Heparin, Low-Molecular-Weight Phase 4
36 Natriuretic Agents Phase 4
37 Deamino Arginine Vasopressin Phase 4
38 arginine Phase 4
39 Vasopressins Phase 4
40 Arginine Vasopressin Phase 4
41 calcium heparin Phase 4
42
protease inhibitors Phase 4
43 Antithrombin III Phase 4
44 HIV Protease Inhibitors Phase 4
45 Serine Proteinase Inhibitors Phase 4
46 Antithrombins Phase 4
47 Factor Xa Inhibitors Phase 4
48 Pharmaceutical Solutions Phase 4
49 Analgesics Phase 4
50 Cyclooxygenase Inhibitors Phase 4
51 Analgesics, Non-Narcotic Phase 4
52 Peripheral Nervous System Agents Phase 4
53 Anti-Inflammatory Agents, Non-Steroidal Phase 4
54 Anti-Inflammatory Agents Phase 4
55 Antirheumatic Agents Phase 4
56 Ketorolac Tromethamine Phase 4
57 Thromboplastin Phase 4
58 Protamines Phase 4
59
Diclofenac Approved, Vet_approved Phase 3 15307-86-5 3033
60
Clopidogrel Approved Phase 3 113665-84-2, 120202-66-6 60606
61
Rivaroxaban Approved Phase 2, Phase 3 366789-02-8
62
Apixaban Approved Phase 3 503612-47-3 10182969
63
Quinidine Approved, Investigational Phase 2, Phase 3 56-54-2 441074
64
Verapamil Approved Phase 2, Phase 3 52-53-9 2520
65
Coumarin Experimental Phase 3 91-64-5 323
66
Fibrinolysin Investigational Phase 3 9004-09-5
67 Anesthetics Phase 3
68 protein S Phase 3
69 Autoantibodies Phase 2, Phase 3
70 Neurotransmitter Agents Phase 3
71 Purinergic P2Y Receptor Antagonists Phase 3
72 Purinergic P2 Receptor Antagonists Phase 3
73 Vitamin K 1 Phase 3
74 Antibodies Phase 3
75 Immunoglobulins Phase 3
76 Fibrin fragment D Phase 2, Phase 3
77 Plasminogen Phase 3
78 Quinidine gluconate Phase 2, Phase 3
79 lysine Phase 3
80
Icodextrin Approved, Investigational Phase 2 337376-15-5
81
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
82
tannic acid Approved Phase 1, Phase 2 1401-55-4
83
Benzocaine Approved, Investigational Phase 1, Phase 2 94-09-7, 1994-09-7 2337
84
Atorvastatin Approved Phase 2 134523-00-5 60823
85
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
86
Ribavirin Approved Phase 2 36791-04-5 37542
87
Ledipasvir Approved Phase 2 1256388-51-8 67505836
88
Morphine Approved, Investigational Phase 2 57-27-2 5288826
89
Ephedrine Approved Phase 2 299-42-3 9294
90
Pseudoephedrine Approved Phase 2 90-82-4 7028
91
Bupivacaine Approved, Investigational Phase 2 2180-92-9, 38396-39-3 2474
92
Atropine Approved, Vet_approved Phase 2 5908-99-6, 51-55-8 174174
93
Tocopherol Approved, Investigational Phase 2 1406-66-2, 54-28-4 14986
94
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
95
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
96
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 54670067 5785
97 Tocotrienol Investigational Phase 2 6829-55-6
98 Citrate Phase 1, Phase 2
99 Lipid Regulating Agents Phase 2
100 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
101 Hypolipidemic Agents Phase 2
102 Autonomic Agents Phase 2
103 Antimetabolites Phase 2
104 Anticholesteremic Agents Phase 2
105 Antiviral Agents Phase 2
106 Anti-Infective Agents Phase 2
107 Janus Kinase Inhibitors Phase 1, Phase 2
108 Anti-Retroviral Agents Phase 2
109 Antivenins Phase 2
110 Sympathomimetics Phase 2
111 Anesthetics, Local Phase 2
112 Parasympatholytics Phase 2
113 Narcotics Phase 2
114 Adrenergic Agents Phase 2
115 Central Nervous System Stimulants Phase 2
116 Respiratory System Agents Phase 2
117 Nasal Decongestants Phase 2
118 Adjuvants, Anesthesia Phase 2
119 Cholinergic Agents Phase 2
120 Muscarinic Antagonists Phase 2
121 Cholinergic Antagonists Phase 2
122 Mydriatics Phase 2
123 Central Nervous System Depressants Phase 2
124 Analgesics, Opioid Phase 2
125 Anti-Arrhythmia Agents Phase 2
126 Anti-Asthmatic Agents Phase 2
127 Vasoconstrictor Agents Phase 2
128 Bronchodilator Agents Phase 2
129 Immunologic Factors Phase 1, Phase 2
130 Antioxidants Phase 2
131 Tocotrienols Phase 2
132 Tocopherols Phase 2
133 Protective Agents Phase 2
134 Protein Kinase Inhibitors Phase 2
135 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 2
136
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
137
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
138
Oxymetazoline Approved, Investigational Phase 1 1491-59-4 4636
139
Phenylephrine Approved Phase 1 59-42-7 6041
140
Lenalidomide Approved Phase 1 191732-72-6 216326
141
Dabigatran Investigational Phase 1 211914-51-1
142 Dacetuzumab Investigational Phase 1 880486-59-9 9953592
143 Immunoglobulin Fc Fragments Phase 1
144 Gastrointestinal Agents Phase 1
145 Antiemetics Phase 1
146 glucocorticoids Phase 1
147 Hormones Phase 1
148 Antineoplastic Agents, Hormonal Phase 1
149 Hormone Antagonists Phase 1
150 BB 1101 Phase 1
151 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
152 Antineoplastic Agents, Immunological Phase 1
153 Antibodies, Monoclonal Phase 1
154 Angiogenesis Inhibitors Phase 1
155 Angiogenesis Modulating Agents Phase 1
156 Adjuvants, Immunologic Phase 1
157 Wobenzym Phase 1
158
Levonorgestrel Approved, Investigational 797-63-7, 17489-40-6 13109
159
Copper Approved, Investigational 7440-50-8 27099
160
Adenosine Approved, Investigational 58-61-7 60961
161
Oprelvekin Approved, Investigational 145941-26-0
162
Mannitol Approved, Investigational 69-65-8 453 6251
163
Sorbitol Approved 50-70-4 5780
164
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
165
Polyestradiol phosphate Approved 28014-46-2
166
Testosterone Approved, Experimental, Investigational 481-30-1, 58-22-0 6013 10204
167
Mercaptopurine Approved 50-44-2 667490
168
Sirolimus Approved, Investigational 53123-88-9 6436030 5284616 46835353
169
Aminocaproic acid Approved, Investigational 60-32-2 564
170
rituximab Approved 174722-31-7 10201696
171
Mycophenolic acid Approved 24280-93-1 446541
172
Xylometazoline Approved, Investigational 526-36-3 5709
173
Aspirin Approved, Vet_approved 50-78-2 2244